1. Stocks
    2. /
  2. Paradigm Biopharmaceuticals Limited (ASX: PAR)
    3. /

Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Paradigm Biopharmaceuticals Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Paradigm Biopharmaceuticals Limited (ASX: PAR)
    Latest News

    A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
    Broker Notes

    Why this exciting ASX stock could rocket 90%!

    | James Mickleboro

    Bell Potter is tipping this stock to almost double in value from current levels.

    Read more »

    Broker looking at the share price.
    Share Market News

    5 things to watch on the ASX 200 on Wednesday

    | James Mickleboro

    Here's what to expect on the local market on hump day.

    Read more »

    Cheerful boyfriend showing mobile phone to girlfriend in dining room. They are spending leisure time together at home and planning their financial future.
    Share Fallers

    Why DroneShield, Neuren, Paradigm, and Pilbara Minerals shares are roaring higher today

    | James Mickleboro

    These shares are having a strong session on Thursday. But why?

    Read more »

    Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
    Healthcare Shares

    2 ASX healthcare stocks making huge moves on big news

    | James Mickleboro

    These shares are getting investors excited today. But why?

    Read more »

    Three health professionals at a hospital smile for the camera.
    Healthcare Shares

    3 ASX healthcare stocks soaring on positive company updates

    | Bronwyn Allen

    These companies have exciting news for investors today.

    Read more »

    A man raises his reading glasses in a look of surprise.
    Small Cap Shares

    Why these small cap ASX shares could deliver very big returns in 2025

    | James Mickleboro

    High risk, high reward is the game with these shares according to analysts.

    Read more »

    group of friends jump on the beach
    Broker Notes

    6 ASX All Ords shares lifted to 'strong buy' consensus ratings for the new year

    | Bronwyn Allen

    Brokers upgraded these ASX stocks last month.

    Read more »

    A businesswoman gets angry, shaking her fist at her computer.
    Share Fallers

    Why ANZ, Calix, Paradigm, and Platinum shares are tumbling today

    | James Mickleboro

    These shares are starting the week in the red. But why?

    Read more »

    A man slumps crankily over his morning coffee as it pours with rain outside.
    Healthcare Shares

    Why is this ASX healthcare stock crashing 26% today?

    | James Mickleboro

    Let's find out what is causing investors to hit the sell button on Monday.

    Read more »

    A man holds his glasses up to his forehead looking gobsmacked over ASX share price rises
    Small Cap Shares

    These small cap ASX shares could surge 27% to 38% higher

    | James Mickleboro

    Let's see why analysts are bullish on these shares and tipping them to surge.

    Read more »

    A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
    Healthcare Shares

    This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt

    | Zach Bristow

    The company requested the pause before the open.

    Read more »

    Rising share price chart.
    Small Cap Shares

    Analysts say these small cap ASX shares could rise 30% and 50%

    | James Mickleboro

    Here's why they are tipping these shares to deliver big returns for investors.

    Read more »

    Frequently Asked Questions

    No, Paradigm does not pay shareholder dividends at this time. 

    Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.

    PAR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Paradigm Biopharmaceuticals Limited

    Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.

    Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe. 

    Profile

    since

    Note